Background

Canagliflozin inhibitor, ine simba, uye inonyanya kusarudza sodium glucose co-transporter (SGLT) 2 inhibitor [1].Zvave zvichiratidzwa kuti Canagliflozin inogona kuwedzera weti glucose kubuda nekudzikisa renal glucose pachikumbaridzo uye nekudzikisa yakasefa glucose kutorwazve.

Canagliflozin yakaratidzwa kuti inhibisa Na+-mediated 14C-AMG kutora mu CHO-hSGLT2, CHO-rat SGLT2 uye CHO-mbeva SGLT2 ine IC50 kukosha kwe4.4, 3.7 uye 2.0 nM, zvichiteerana [1].

Canagliflozin inonzi inoderedza mazinga eglucose (BG) mazinga-zvichienderana mune ese ari maviri db/db Mice uye Zucker Diabetic Fatty (ZDF) Rats.Pamusoro pezvo, canagliflozin yakaratidza kudzikisira reshiyo yekufema, uye huremu hwemuviri muDIO mbeva nemakonzo eZDF [1].

Kanagliflozin inogona kutorwa nemuromo [1].

References:
[1] Liang Y1, Arakawa K, Ueta K, Matsushita Y, Kuriyama C Martin T, Du F, Liu Y, Xu J, Conway B, Conway J, Polidori D, Ways K, Demarest K. Mhedzisiro yecanagliflozin pachikumbaridzo chetsvo yeglucose, glycemia, uye uremu hwemuviri mumhando dzemhuka dzakajairwa uye dzeshuga.PLoS Imwe.2012;7(2):e30555
[2] Sarnoski-Brocavich S, Hilas O. Canagliflozin (Invokana), Novel Oral Agent For Type-2 Diabetes.P T. 2013 Nov;38(11):656-66

Product Citation

Bahia Abbas Moussa, Marianne Alphonse Mahrouse, et al."Matanho akasiyana ekugadzirisa ekutungamira kweakaputirana spectra: Chikumbiro chekutsvaga kweinoveli co-formulated hypoglycemic zvinodhaka mune yavo yakasanganiswa yemishonga fomu."Spectrochimica Acta Chikamu A: Molecular uye Biomolecular Spectroscopy Inowanikwa online 20 June 2018.

Chimiro chemakemikari